Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Alendronate/Alendronate	2,047
Overall Study	STARTED	Romosozumab/Alendronate	2,046
Overall Study	Received Double-blind Treatment	Alendronate/Alendronate	2,040
Overall Study	Received Double-blind Treatment	Romosozumab/Alendronate	2,038
Overall Study	Completed Double-blind Period	Alendronate/Alendronate	1,823
Overall Study	Completed Double-blind Period	Romosozumab/Alendronate	1,831
Overall Study	Completed Primary Analysis Period	Alendronate/Alendronate	1,576
Overall Study	Completed Primary Analysis Period	Romosozumab/Alendronate	1,574
Overall Study	COMPLETED	Alendronate/Alendronate	1,503
Overall Study	COMPLETED	Romosozumab/Alendronate	1,523
Overall Study	NOT COMPLETED	Alendronate/Alendronate	544
Overall Study	NOT COMPLETED	Romosozumab/Alendronate	523

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01631214/flow